Cargando…

Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!

BACKGROUND: The risk of thromboembolic events is higher among cancer patients, especially in patients undergoing chemotherapy. Cisplatin-based regimens claim to be associated with a very high thromboembolic rate. In this study, we report on our own experience with thrombosis among patients on active...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Razeq, Hikmat, Mansour, Asem, Abdulelah, Hazem, Al-Shwayat, Anas, Makoseh, Mohammad, Ibrahim, Mohammad, Abunasser, Mahmoud, Rimawi, Dalia, Al-Rabaiah, Abeer, Alfar, Rozan, Abufara, Alaa’, Ibrahim, Alaa, Bawaliz, Anas, Ismael, Yousef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831696/
https://www.ncbi.nlm.nih.gov/pubmed/29507532
http://dx.doi.org/10.1186/s12959-018-0161-9
_version_ 1783303184122380288
author Abdel-Razeq, Hikmat
Mansour, Asem
Abdulelah, Hazem
Al-Shwayat, Anas
Makoseh, Mohammad
Ibrahim, Mohammad
Abunasser, Mahmoud
Rimawi, Dalia
Al-Rabaiah, Abeer
Alfar, Rozan
Abufara, Alaa’
Ibrahim, Alaa
Bawaliz, Anas
Ismael, Yousef
author_facet Abdel-Razeq, Hikmat
Mansour, Asem
Abdulelah, Hazem
Al-Shwayat, Anas
Makoseh, Mohammad
Ibrahim, Mohammad
Abunasser, Mahmoud
Rimawi, Dalia
Al-Rabaiah, Abeer
Alfar, Rozan
Abufara, Alaa’
Ibrahim, Alaa
Bawaliz, Anas
Ismael, Yousef
author_sort Abdel-Razeq, Hikmat
collection PubMed
description BACKGROUND: The risk of thromboembolic events is higher among cancer patients, especially in patients undergoing chemotherapy. Cisplatin-based regimens claim to be associated with a very high thromboembolic rate. In this study, we report on our own experience with thrombosis among patients on active cisplatin-based chemotherapy. METHODS: Medical records and hospital databases were searched for all the patients treated with any cisplatin-based regimen for any kind of cancer. Thrombosis was considered cisplatin-related if diagnosed any time after the first dose and up to 4 weeks after the last. The Khorana risk assessment model was performed in all cases. RESULTS: A total of 1677 patients (65.5% males, median age: 50 years) treated with cisplatin-based regimens were identified. Head and neck (22.9%), lung (22.2%), lymphoma and gastric (11.4% each) were the most common primary tumors. Thromboembolic events were reported in 110 (6.6%); the highest was in patients with gastric cancer (20.9%) and the lowest in patients with head and neck cancers (2.3%) and lymphoma (1.6%). Thrombosis included deep vein thrombosis (DVT) in 69 (62.7%), pulmonary embolism (PE) in 18 (16.9%) and arterial thrombosis in 17 (15.6%). A majority (51.1%) of the patients had stage IV disease and only 16% had stage I or II. In a multivariate analysis, significantly higher rates of thrombosis were associated with gastric as the primary tumor, advanced-stage disease, female sex but not age, and the Khorana risk score or type of cisplatin regimen. While the presence of CVC was significantly associated with the risk of thrombosis (p < 0.0001) in the univariate analysis, and such significance was lost in the multivariate analysis (odds ratio, 1.098; 95%CI, 0.603–1.999, p = 0.7599). CONCLUSIONS: Thromboembolic events in cancer patients on active cisplatin-based chemotherapy were commonly encountered. Gastric cancer, regardless of other clinical variables, was associated with the highest risk.
format Online
Article
Text
id pubmed-5831696
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58316962018-03-05 Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! Abdel-Razeq, Hikmat Mansour, Asem Abdulelah, Hazem Al-Shwayat, Anas Makoseh, Mohammad Ibrahim, Mohammad Abunasser, Mahmoud Rimawi, Dalia Al-Rabaiah, Abeer Alfar, Rozan Abufara, Alaa’ Ibrahim, Alaa Bawaliz, Anas Ismael, Yousef Thromb J Research BACKGROUND: The risk of thromboembolic events is higher among cancer patients, especially in patients undergoing chemotherapy. Cisplatin-based regimens claim to be associated with a very high thromboembolic rate. In this study, we report on our own experience with thrombosis among patients on active cisplatin-based chemotherapy. METHODS: Medical records and hospital databases were searched for all the patients treated with any cisplatin-based regimen for any kind of cancer. Thrombosis was considered cisplatin-related if diagnosed any time after the first dose and up to 4 weeks after the last. The Khorana risk assessment model was performed in all cases. RESULTS: A total of 1677 patients (65.5% males, median age: 50 years) treated with cisplatin-based regimens were identified. Head and neck (22.9%), lung (22.2%), lymphoma and gastric (11.4% each) were the most common primary tumors. Thromboembolic events were reported in 110 (6.6%); the highest was in patients with gastric cancer (20.9%) and the lowest in patients with head and neck cancers (2.3%) and lymphoma (1.6%). Thrombosis included deep vein thrombosis (DVT) in 69 (62.7%), pulmonary embolism (PE) in 18 (16.9%) and arterial thrombosis in 17 (15.6%). A majority (51.1%) of the patients had stage IV disease and only 16% had stage I or II. In a multivariate analysis, significantly higher rates of thrombosis were associated with gastric as the primary tumor, advanced-stage disease, female sex but not age, and the Khorana risk score or type of cisplatin regimen. While the presence of CVC was significantly associated with the risk of thrombosis (p < 0.0001) in the univariate analysis, and such significance was lost in the multivariate analysis (odds ratio, 1.098; 95%CI, 0.603–1.999, p = 0.7599). CONCLUSIONS: Thromboembolic events in cancer patients on active cisplatin-based chemotherapy were commonly encountered. Gastric cancer, regardless of other clinical variables, was associated with the highest risk. BioMed Central 2018-03-01 /pmc/articles/PMC5831696/ /pubmed/29507532 http://dx.doi.org/10.1186/s12959-018-0161-9 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Abdel-Razeq, Hikmat
Mansour, Asem
Abdulelah, Hazem
Al-Shwayat, Anas
Makoseh, Mohammad
Ibrahim, Mohammad
Abunasser, Mahmoud
Rimawi, Dalia
Al-Rabaiah, Abeer
Alfar, Rozan
Abufara, Alaa’
Ibrahim, Alaa
Bawaliz, Anas
Ismael, Yousef
Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!
title Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!
title_full Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!
title_fullStr Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!
title_full_unstemmed Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!
title_short Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!
title_sort thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831696/
https://www.ncbi.nlm.nih.gov/pubmed/29507532
http://dx.doi.org/10.1186/s12959-018-0161-9
work_keys_str_mv AT abdelrazeqhikmat thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook
AT mansourasem thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook
AT abdulelahhazem thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook
AT alshwayatanas thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook
AT makosehmohammad thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook
AT ibrahimmohammad thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook
AT abunassermahmoud thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook
AT rimawidalia thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook
AT alrabaiahabeer thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook
AT alfarrozan thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook
AT abufaraalaa thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook
AT ibrahimalaa thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook
AT bawalizanas thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook
AT ismaelyousef thromboemboliceventsincancerpatientsonactivetreatmentwithcisplatinbasedchemotherapyanotherlook